性活动问卷在子宫内膜异位症女性中的验证
在法国两家三级诊疗中心开展观察性研究,纳入367例子宫内膜异位症女性,其中267例有性生活者构成基线人群。SAQ在手术治疗患者中具有反应性但效应量低(0.3,95%CI 0.0-0.6,P=0.01),最小重要差异为2.2。作者推荐将2.2作为SAQ的最小重要差异值。
要点
- SAQ在子宫内膜异位症患者中具有良好内部一致性(Cronbach α=0.78,95%CI 0.74-0.81)。
- SAQ在手术治疗患者中有反应性,但效应量低(0.3,95%CI 0.0-0.6,P=0.01)。
- SAQ的最小重要差异确定为2.2,作者推荐用于未来研究。
核心结论
- 对于接受手术治疗的子宫内膜异位症女性,SAQ是有效且具有反应性的工具。
- SAQ易于使用、有效,可用于评估子宫内膜异位症患者的性生活质量。
研究设计与样本
- 观察性研究,于2012年1月1日至2014年12月31日在法国两家三级诊疗中心开展。
- 共纳入367例经证实的子宫内膜异位症女性,接受药物或手术治疗;其中267例有性生活者构成基线人群。
- 纳入标准为年龄>18岁、组织学或影像学证实的子宫内膜异位症,因疼痛症状持续至少3个月、不孕或其他症状(出血、囊肿)就诊。
- 受试者在治疗前(T0)和治疗后12个月(T1)完成自填问卷。
主要发现
- 267例有性生活患者中,204例接受手术治疗,63例接受药物治疗;T0时完成SAQ,T1时136例(50.9%)完成。
- SAQ评分范围为2.0至28.0(均值±标准差:16.8±5.7)。
- 根据碎石图,SAQ为单维度,内部一致性良好(Cronbach α=0.78,95%CI 0.74-0.81)。
- SAQ在手术治疗患者中具有反应性,但效应量低(0.3,95%CI 0.0-0.6,P=0.01)。
- 药物治疗的效应量无统计学意义;其他效应量低但具有统计学意义。
关键数值与推荐
- SAQ最小重要差异确定为2.2。
- 作者推荐将2.2作为SAQ的最小重要差异值。
临床怎么用
- SAQ易于使用、有效,可用于评估子宫内膜异位症患者的性生活质量。
- 作者认为该患者报告评分可作为未来临床研究的主要结局指标。
- 最小重要差异的估计将有助于未来研究。
局限性
- 药物治疗的效应量无统计学意义。
- 其他效应量低但具有统计学意义。
- 作者解释这可能与孕激素摄入导致性欲降低有关,孕激素在手术和药物治疗患者中均有使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is the Sexual Activity Questionnaire (SAQ) a valid tool for patients treated for symptomatic endometriosis? SUMMARY ANSWER: For women having surgical treatment for endometriosis, we determined that the SAQ is a valid and responsive tool. WHAT IS KNOWN ALREADY: Endometriosis adversely affects sexual quality of life. Suitable validated sexual quality of life instruments for endometriosis are lacking both in clinical practice and for research. STUDY, DESIGN, SIZE, DURATION: A total of 367 women with proven endometriosis undergoing medical or surgical treatment were included in an observational study conducted between 1 January 2012 and 31 December 2014 in two French tertiary care centers. Both hospitals are reference centers for endometriosis treatment. Of these 367 women, 267 were sexually active and constituted the baseline population. PARTICPANTS/MATERIALS, SETTINGS, METHODS: Women >18 years old with histological or radiological proven endometriosis, consulting for painful symptoms of at least 3 months duration, infertility, or other symptoms (bleeding, cysts) were invited to complete self-administered questionnaires before (T0) and 12 months after treatment (T1). Tests of data quality included descriptive statistics of the data, missing data levels, floor and ceiling effects, structural validity and internal consistency.The construct validity was obtained by testing presupposed relationships between previously established SAQ scores and prespecified characteristics of the patients by comparing different subgroups of patients at T0. Sensitivity to change was subsequently calculated by comparing the SAQ score between T1 and T0 overall and for different subgroups of treatment. Effect sizes (to T1) were calculated according to Cohen's method. The minimally important difference was estimated by a step-wise triangulation approach (including anchor-based method). MAIN RESULTS AND THE ROLE OF CHANCE: In total, 267 sexually active patients (204 surgical and 63 medical treatment) completed the SAQ at T0 and 136 (50.9%) at T1. The SAQ score ranged from 2.0 to 28.0 (mean ± SD: 16.8 ± 5.7).The SAQ score was one-dimensional according to the scree plot with good internal consistency (Cronbach alpha = 0.78, 95% CI 0.74-0.81) and had good discriminative ability according to pain descriptors and quality of life in endometriosis. The SAQ was responsive in patients treated by surgery but the effect size was low (0.3, 95% CI (0.0-0.6), P = 0.01). The minimally important difference was determined at 2.2. LIMITATIONS, REASONS FOR CAUTION: The effect size for medical treatment was non-significant. Other effect sizes were low but statistically significant. This could be explained by lower libido due to progestin intake, which was used for both surgically and medically treated patients. WIDER IMPLICATIONS OF THE FINDINGS: The SAQ is easy to use, valid and effective in assessing sexual quality of life in patients with endometriosis. This patient-reported score could be used as a primary outcome for future clinical studies. The minimally important difference estimation will be useful for future research. We recommend using 2.2 for the minimally important difference of the SAQ. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the 'Direction à la Recherche Clinique et à l'Innovation' of Versailles, France and the 'Institut de Recherche en Santé de la Femme' (IRSF). The authors have no conflicts of interest to declare.
引用
- Oppenheimer A, Panel P, Rouquette A, et al. Validation of the Sexual Activity Questionnaire in women with endometriosis. Hum Reprod. 2019. PMID: 30989214. doi:10.1093/humrep/dez037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。